Apolipoprotein-defined lipoprotein abnormalities in rheumatoid arthritis patients and their potential impact on cardiovascular disease

References

• Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, . Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum 2008;58: 15–25.
   PubMed Web of Science ®Google Scholar
• Koopman WJ. Prospects for autoimmune disease: research advances in rheumatoid arthritis. J Am Med Assoc 2001;285:648–50.
   Google Scholar
• Wolfe F, Freundlich B, Straus WL. Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J Rheumatol 2003;30:36–40.
   PubMed Web of Science ®Google Scholar
• Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, . Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003; 107:1303–7.
   PubMed Web of Science ®Google Scholar
• Watson DJ, Rhodes T, Guess HA. All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database. J Rheumatol 2003;30:1196–202.
   PubMed Web of Science ®Google Scholar
• del Rincon I, Freeman GL, Haas RW, O’Leary DH, Escalante A. Relative contribution of cardiovascular risk factors and rheumatoid arthritis clinical manifestations to atherosclerosis. Arthritis Rheum 2005;52:3413–23.
   PubMed Web of Science ®Google Scholar
• Toms TE, Symmons DP, Kitas GD. Dyslipidaemia in rheumatoid arthritis: the role of inflammation, drugs, lifestyle and genetic factors. Curr Vasc Pharmacol 2010;8:301–26.
   PubMed Web of Science ®Google Scholar
• Tam LS, Li E, Shang Q, Tomlinson B, Lee V, Lee K, . Effects of rosuvastatin on subclinical atherosclerosis and arterial stiffness in rheumatoid arthritis: a randomized controlled pilot trial. Scand J Rheumatol 2011;40:411–21.
   PubMed Web of Science ®Google Scholar
• Vuilleumier N, Bratt J, Alizadeh R, Jogestrand T, Hafstrom I, Frostegard J. Anti-apoA-1 IgG and oxidized LDL are raised in rheumatoid arthritis (RA): potential associations with cardiovascular disease and RA disease activity. Scand J Rheumatol 2010;39:447–53.
   PubMed Web of Science ®Google Scholar
• del Rincon ID, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001;44:2737–45.
   PubMed Web of Science ®Google Scholar
• Dessein PH, Tobias M, Veller MG. Metabolic syndrome and subclinical atherosclerosis in rheumatoid arthritis. J Rheumatol 2006;33:2425–32.
   PubMed Web of Science ®Google Scholar
• Gonzalez A, Maradit Kremers H, Crowson CS, Ballman KV, Roger VL, Jacobsen SJ, . Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients? Ann Rheum Dis 2008;67:64–9.
   PubMed Web of Science ®Google Scholar
• Choy E, Sattar N. Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann Rheum Dis 2009;68:460–9.
   PubMed Web of Science ®Google Scholar
• Boyer JF, Gourraud PA, Cantagrel A, Davignon JL, Constantin A. Traditional cardiovascular risk factors in rheumatoid arthritis: a meta-analysis. Joint Bone Spine 2011;78:179–83.
   PubMed Web of Science ®Google Scholar
• Alaupovic P. The concept of apolipoprotein-defined lipoprotein families and its clinical significance. Curr Atheroscler Rep 2003;5:459–67.
   PubMedGoogle Scholar
• Blankenhorn DH, Johnson RL, Mack WJ, el Zein HA, Vailas LI. The influence of diet on the appearance of new lesions in human coronary arteries. J Am Med Assoc 1990;263:1646–52.
   Google Scholar
• Wang CS, McConathy WJ, Kloer HU, Alaupovic P. Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III. J Clin Invest 1985;75:384–90.
   PubMed Web of Science ®Google Scholar
• Clavey V, Lestavel-Delattre S, Copin C, Bard JM, Fruchart JC. Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII, CIII, and E. Arterioscler Thromb Vasc Biol 1995;15:963–71.
   PubMed Web of Science ®Google Scholar
• Kawakami A, Aikawa M, Libby P, Alcaide P, Luscinskas FW, Sacks FM. Apolipoprotein CIII in apolipoprotein B lipoproteins enhances the adhesion of human monocytic cells to endothelial cells. Circulation 2006;113:691–700.
   PubMed Web of Science ®Google Scholar
• Kawakami A, Yoshida M. Apolipoprotein CIII links dyslipidemia with atherosclerosis. J Atheroscler Thromb 2009;16:6–11.
   PubMed Web of Science ®Google Scholar
• Alaupovic P, Mack WJ, Knight-Gibson C, Hodis HN. The role of triglyceride-rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial. Arterioscler Thromb Vasc Biol 1997;17:715–22.
   PubMed Web of Science ®Google Scholar
• Hodis HN, Mack WJ, Azen SP, Alaupovic P, Pogoda JM, LaBree L, . Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation 1994;90:42–9.
   PubMed Web of Science ®Google Scholar
• Sacks FM, Alaupovic P, Moye LA, Cole TG, Sussex B, Stampfer MJ, . VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation 2000;102:1886–92.
   PubMed Web of Science ®Google Scholar
• Gervaise N, Garrigue MA, Lasfargues G, Lecomte P. Triglycerides, apo C3 and Lp B:C3 and cardiovascular risk in type II diabetes. Diabetologia 2000;43:703–8.
   PubMed Web of Science ®Google Scholar
• Wang CS, Alaupovic P, Gregg RE, Brewer HB Jr. Studies on the mechanism of hypertriglyceridemia in Tangier disease. Determination of plasma lipolytic activities, k1 values and apolipoprotein composition of the major lipoprotein density classes. Biochim Biophys Acta 1987;920:9–19.
   PubMedGoogle Scholar
• Warnick GR, Albers JJ. A comprehensive evaluation of the heparin-manganese precipitation procedure for estimating high density lipoprotein cholesterol. J Lipid Res 1978;19:65–76.
   PubMed Web of Science ®Google Scholar
• Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499–502.
   PubMed Web of Science ®Google Scholar
• Riepponen P, Marniemi J, Rautaoja T. Immunoturbidimetric determination of apolipoproteins A-1 and B in serum. Scand J Clin Lab Invest 1987;47:739–44.
   PubMed Web of Science ®Google Scholar
• Curry MD, Alaupovic P, Suenram CA. Determination of apolipoprotein A and its constitutive A-I and A-II polypeptides by separate electroimmunoassays. Clin Chem 1976;22:315–22.
   PubMed Web of Science ®Google Scholar
• Curry MD, McConathy WJ, Fesmire JD, Alaupovic P. Quantitative determination of human apolipoprotein C-III by electroimmunoassay. Biochim Biophys Acta 1980;617:503–13.
   PubMedGoogle Scholar
• Curry MD, McConathy WJ, Alaupovic P, Ledford JH, Popovic M. Determination of human apolipoprotein E by electroimmunoassay. Biochim Biophys Acta 1976;439:413–25.
   PubMedGoogle Scholar
• Attman PO, Samuelsson O, Alaupovic P. Lipoprotein metabolism and renal failure. Am J Kidney Dis 1993;21:573–92.
   PubMed Web of Science ®Google Scholar
• Marz W, Trommlitz M, Gross W. Differential turbidimetric assay for subpopulations of lipoproteins containing apolipoprotein A-I. J Clin Chem Clin Biochem 1988;26:573–8.
   PubMedGoogle Scholar
• Hilpert KF, West SG, Kris-Etherton PM, Hecker KD, Simpson NM, Alaupovic P. Postprandial effect of n-3 polyunsaturated fatty acids on apolipoprotein B-containing lipoproteins and vascular reactivity in type 2 diabetes. Am J Clin Nutr 2007;85:369–76.
   PubMedGoogle Scholar
• Dunn OJ. Multiple comparisions among means. J Am Stat Assoc 1961;56:52–64.
   Web of Science ®Google Scholar
• Walldius G, Jungner I. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy – a review of the evidence. J Intern Med 2006;259:493–519.
   PubMed Web of Science ®Google Scholar
• Park YB, Lee SK, Lee WK, Suh CH, Lee CW, Lee CH, . Lipid profiles in untreated patients with rheumatoid arthritis. J Rheumatol 1999;26:1701–4.
   PubMed Web of Science ®Google Scholar
• Yoo WH. Dyslipoproteinemia in patients with active rheumatoid arthritis: effects of disease activity, sex, and menopausal status on lipid profiles. J Rheumatol 2004;31:1746–53.
   PubMed Web of Science ®Google Scholar
• Alaupovic P, Mack WJ, Knight-Gibson C, Hodis HN. The role of triglyceride-rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial. Arterioscler Thromb Vasc Biol 1997;17:715–22.
   PubMed Web of Science ®Google Scholar
• Mendivil CO, Rimm EB, Furtado J, Chiuve SE, Sacks FM. Low-density lipoproteins containing apolipoprotein C-III and the risk of coronary heart disease. Circulation 2011;124:2065–72.
   PubMed Web of Science ®Google Scholar
• Alaupovic P, Knight-Gibson C, Wang CS, Downs D, Koren E, Brewer HB Jr, . Isolation and characterization of an apoA-II-containing lipoprotein (LP-A-II:B complex) from plasma very low density lipoproteins of patients with Tangier disease and type V hyperlipoproteinemia. J Lipid Res 1991;32:9–19.
   PubMed Web of Science ®Google Scholar
• Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996;3:213–19.
   PubMedGoogle Scholar
• Hodis HN, Mack WJ, Krauss RM, Alaupovic P. Pathophysiology of triglyceride-rich lipoproteins in atherothrombosis: clinical aspects. Clin Cardiol 1999;22:II15–20.
   PubMed Web of Science ®Google Scholar
• Koren E, Corder C, Mueller G, Centurion H, Hallum G, Fesmire J, . Triglyceride enriched lipoprotein particles correlate with the severity of coronary artery disease. Atherosclerosis 1996;122: 105–15.
   PubMed Web of Science ®Google Scholar
• Lee SJ, Campos H, Moye LA, Sacks FM. LDL containing apolipoprotein CIII is an independent risk factor for coronary events in diabetic patients. Arterioscler Thromb Vasc Biol 2003;23:853–8.
   PubMed Web of Science ®Google Scholar
• Koren E, Koscec M, Knight-Gibson C. Differential uptake of ApoB-containing lipoproteins by THP-1 macrophages. Abstracts of the Council on Arteriosclerosis for the 66th scientific sessions of the American Heart Association, Atlanta, Gorgia: 1993 November 8–11, 1993; Abstract 68.
   Google Scholar